CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Bookmark and Share
Published: 17 Jun 2021
Views: 262
Rating:
Save
Prof John Allan - Weill Cornell Medicine, New York, USA

Prof John Allan speaks to ecancer in an online interview for the EHA 2021 virtual meeting about the primary analysis of the CAPTIVATE study.

He explains that the phase II study looked at first-line ibrutinib plus venetoclax for chronic lymphocytic leukaemia / small lymphocytic lymphoma, and focuses on talking about the fixed-duration cohort. He notes that this is an all-oral, once-daily, chemotherapy-free regimen.

Prof Allan reports that this treatment showed favourable, safe and effective results in this patient cohort, and says that this is promising for opening up a new treatment option for these patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.